PMID- 35673508
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230123
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 21
IP  - 1
DP  - 2022 Jun
TI  - Effects of alcoholic extract of Terminalia Chebula dried fruit on blood 
      biochemical profile in diabetic rats.
PG  - 159-170
LID - 10.1007/s40200-021-00951-8 [doi]
AB  - BACKGROUND: A considerable amount of attention has been recently paid to the 
      discovery of effective natural antidiabetic drugs. Terminalia chebula is 
      considered as the mother of herbs, with reported antidiabetic activity. This 
      study aims to evaluate the renal and hepatic protective profile of its 
      antidiabetic therapeutic doses. METHODS: To achieve the aim of the study, a total 
      of 66 adult male rats of Sprague-Dawley species weighing about 180-200 g (weighed 
      using a digital scale) were used. Type 2 diabetes mellitus (T2DM) was induced in 
      using streptozotocin (STZ), rats were given a 5% dextrose solution for the next 
      24 h. Subjects received oral treatment of Terminalia chebula ethanolic extract at 
      different doses (200, 400, and 600 mg/kg body weight) for 28 days. Measurements 
      of fasting blood glucose level, change in body weight, lipid profile, serum liver 
      enzymes, serum renal parameter, and histopathology of liver and kidney were 
      carried out. RESULTS: Higher doses of Terminalia chebula (600 mg/Kg) were shown 
      to have a potential therapeutic effect as well as the most prominent 
      antidiabetic, antilipidemic activity, hepatoprotective and renoprotective 
      profiles when compared to lower doses. CONCLUSION: The use of Terminalia chebula 
      alone or in combination with conventional antidiabetic drugs may be beneficial as 
      a new advent therapy for diabetes. SUPPLEMENTARY INFORMATION: The online version 
      contains supplementary material available at 10.1007/s40200-021-00951-8.
CI  - (c) Springer Nature Switzerland AG 2021.
FAU - Eltimamy, Maha
AU  - Eltimamy M
AD  - Damietta Oncology Centre, Damietta, Egypt.
FAU - Elshamarka, Marwa
AU  - Elshamarka M
AD  - Department of Toxicology and Narcotics, Medical Division, National Research 
      Centre, Damietta, Egypt. GRID: grid.419725.c. ISNI: 0000 0001 2151 8157
FAU - Aboelsaad, Marina
AU  - Aboelsaad M
AD  - Department of Clinical Pharmacy Practice, Faculty of Pharmacy, The British 
      University in Egypt, El Shorouk City, Egypt. GRID: grid.440862.c. ISNI: 0000 0004 
      0377 5514
FAU - Sayed, Moustafa
AU  - Sayed M
AD  - Department of Clinical Pharmacy Practice, Faculty of Pharmacy, The British 
      University in Egypt, El Shorouk City, Egypt. GRID: grid.440862.c. ISNI: 0000 0004 
      0377 5514
FAU - Moawad, Helmy
AU  - Moawad H
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, 
      Cairo, Egypt. GRID: grid.7776.1. ISNI: 0000 0004 0639 9286
LA  - eng
PT  - Journal Article
DEP - 20220122
PL  - Switzerland
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC9167356
OTO - NOTNLM
OT  - Streptozotocin
OT  - T2DM
OT  - Terminalia chebula
COIS- Conflict of interestThe authors declared that they have no conflict of interest.
EDAT- 2022/06/09 06:00
MHDA- 2022/06/09 06:01
PMCR- 2023/01/22
CRDT- 2022/06/08 01:57
PHST- 2021/05/28 00:00 [received]
PHST- 2021/12/02 00:00 [accepted]
PHST- 2022/06/08 01:57 [entrez]
PHST- 2022/06/09 06:00 [pubmed]
PHST- 2022/06/09 06:01 [medline]
PHST- 2023/01/22 00:00 [pmc-release]
AID - 951 [pii]
AID - 10.1007/s40200-021-00951-8 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2022 Jan 22;21(1):159-170. doi: 
      10.1007/s40200-021-00951-8. eCollection 2022 Jun.